Literature DB >> 34130532

The Use of Informer Sets in Screening: Perspectives on an Efficient Strategy to Identify New Probes.

Paul A Clemons1, Joshua A Bittker2,3, Florence F Wagner2, Allison Hands2, Vlado Dančík1, Stuart L Schreiber1, Amit Choudhary1, Bridget K Wagner1.   

Abstract

Small-molecule discovery typically involves large-scale screening campaigns, spanning multiple compound collections. However, such activities can be cost- or time-prohibitive, especially when using complex assay systems, limiting the number of compounds tested. Further, low hit rates can make the process inefficient. Sparse coverage of chemical structure or biological activity space can lead to limited success in a primary screen and represents a missed opportunity by virtue of selecting the "wrong" compounds to test. Thus, the choice of screening collections becomes of paramount importance. In this perspective, we discuss the utility of generating "informer sets" for small-molecule discovery, and how this strategy can be leveraged to prioritize probe candidates. While many researchers may assume that informer sets are focused on particular targets (e.g., kinases) or processes (e.g., autophagy), efforts to assemble informer sets based on historical bioactivity or successful human exposure (e.g., repurposing collections) have shown promise as well. Another method for generating informer sets is based on chemical structure, particularly when the compounds have unknown activities and targets. We describe our efforts to screen an informer set representing a collection of 100,000 small molecules synthesized through diversity-oriented synthesis (DOS). This process enables researchers to identify activity early and more extensively screen only a few chemical scaffolds, rather than the entire collection. This elegant and economic outcome is a goal of the informer set approach. Here, we aim not only to shed light on this process, but also to promote the use of informer sets more widely in small-molecule discovery projects.

Entities:  

Keywords:  chemoinformatics; compound repositories; general pharmaceutical process; high-content screening

Mesh:

Substances:

Year:  2021        PMID: 34130532      PMCID: PMC8991386          DOI: 10.1177/24725552211019410

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  45 in total

1.  An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.

Authors:  Amrita Basu; Nicole E Bodycombe; Jaime H Cheah; Edmund V Price; Ke Liu; Giannina I Schaefer; Richard Y Ebright; Michelle L Stewart; Daisuke Ito; Stephanie Wang; Abigail L Bracha; Ted Liefeld; Mathias Wawer; Joshua C Gilbert; Andrew J Wilson; Nicolas Stransky; Gregory V Kryukov; Vlado Dancik; Jordi Barretina; Levi A Garraway; C Suk-Yee Hon; Benito Munoz; Joshua A Bittker; Brent R Stockwell; Dineo Khabele; Andrew M Stern; Paul A Clemons; Alykhan F Shamji; Stuart L Schreiber
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

2.  Scaffold composition and biological relevance of screening libraries.

Authors:  Anang A Shelat; R Kiplin Guy
Journal:  Nat Chem Biol       Date:  2007-08       Impact factor: 15.040

3.  Rethinking molecular similarity: comparing compounds on the basis of biological activity.

Authors:  Paula M Petrone; Benjamin Simms; Florian Nigsch; Eugen Lounkine; Peter Kutchukian; Allen Cornett; Zhan Deng; John W Davies; Jeremy L Jenkins; Meir Glick
Journal:  ACS Chem Biol       Date:  2012-05-31       Impact factor: 5.100

4.  A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9.

Authors:  Basudeb Maji; Soumyashree A Gangopadhyay; Miseon Lee; Mengchao Shi; Peng Wu; Robert Heler; Beverly Mok; Donghyun Lim; Sachini U Siriwardena; Bishwajit Paul; Vlado Dančík; Amedeo Vetere; Michael F Mesleh; Luciano A Marraffini; David R Liu; Paul A Clemons; Bridget K Wagner; Amit Choudhary
Journal:  Cell       Date:  2019-05-02       Impact factor: 41.582

5.  Connecting Small Molecules with Similar Assay Performance Profiles Leads to New Biological Hypotheses.

Authors:  Vlado Dančík; Hyman Carrel; Nicole E Bodycombe; Kathleen Petri Seiler; Dina Fomina-Yadlin; Stefan T Kubicek; Kimberly Hartwell; Alykhan F Shamji; Bridget K Wagner; Paul A Clemons
Journal:  J Biomol Screen       Date:  2014-01-24

6.  Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes.

Authors:  Mark-Anthony Bray; Shantanu Singh; Han Han; Chadwick T Davis; Blake Borgeson; Cathy Hartland; Maria Kost-Alimova; Sigrun M Gustafsdottir; Christopher C Gibson; Anne E Carpenter
Journal:  Nat Protoc       Date:  2016-08-25       Impact factor: 13.491

Review 7.  Advances in discovering small molecules to probe protein function in a systems context.

Authors:  Shelby K Doyle; Marius S Pop; Helen L Evans; Angela N Koehler
Journal:  Curr Opin Chem Biol       Date:  2015-11-23       Impact factor: 8.822

8.  The Drug Repurposing Hub: a next-generation drug library and information resource.

Authors:  Steven M Corsello; Joshua A Bittker; Zihan Liu; Joshua Gould; Patrick McCarren; Jodi E Hirschman; Stephen E Johnston; Anita Vrcic; Bang Wong; Mariya Khan; Jacob Asiedu; Rajiv Narayan; Christopher C Mader; Aravind Subramanian; Todd R Golub
Journal:  Nat Med       Date:  2017-04-07       Impact factor: 53.440

Review 9.  Composition and applications of focus libraries to phenotypic assays.

Authors:  Anne Mai Wassermann; Luiz M Camargo; Douglas S Auld
Journal:  Front Pharmacol       Date:  2014-07-24       Impact factor: 5.810

10.  Predicting kinase inhibitors using bioactivity matrix derived informer sets.

Authors:  Huikun Zhang; Spencer S Ericksen; Ching-Pei Lee; Gene E Ananiev; Nathan Wlodarchak; Peng Yu; Julie C Mitchell; Anthony Gitter; Stephen J Wright; F Michael Hoffmann; Scott A Wildman; Michael A Newton
Journal:  PLoS Comput Biol       Date:  2019-08-05       Impact factor: 4.475

View more
  4 in total

1.  Bayes optimal informer sets for early-stage drug discovery.

Authors:  Peng Yu; Spencer Ericksen; Anthony Gitter; Michael A Newton
Journal:  Biometrics       Date:  2022-02-15       Impact factor: 1.701

2.  Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity.

Authors:  Jonnell C Small; Aidan Joblin-Mills; Kaycee Carbone; Maria Kost-Alimova; Kumiko Ayukawa; Carol Khodier; Vlado Dancik; Paul A Clemons; Andrew B Munkacsi; Bridget K Wagner
Journal:  ACS Chem Biol       Date:  2022-04-19       Impact factor: 4.634

3.  Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology.

Authors:  Frances M Potjewyd; Joel K Annor-Gyamfi; Jeffrey Aubé; Shaoyou Chu; Ivie L Conlon; Kevin J Frankowski; Shiva K R Guduru; Brian P Hardy; Megan D Hopkins; Chizuru Kinoshita; Dmitri B Kireev; Emily R Mason; Charles T Moerk; Felix Nwogbo; Kenneth H Pearce; Timothy I Richardson; David A Rogers; Disha M Soni; Michael Stashko; Xiaodong Wang; Carrow Wells; Timothy M Willson; Stephen V Frye; Jessica E Young; Alison D Axtman
Journal:  Alzheimers Dement (N Y)       Date:  2022-04-12

4.  AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery.

Authors:  Frances M Potjewyd; Joel K Annor-Gyamfi; Jeffrey Aubé; Shaoyou Chu; Ivie L Conlon; Kevin J Frankowski; Shiva K R Guduru; Brian P Hardy; Megan D Hopkins; Chizuru Kinoshita; Dmitri B Kireev; Emily R Mason; Charles T Moerk; Felix Nwogbo; Kenneth H Pearce; Timothy I Richardson; David A Rogers; Disha M Soni; Michael Stashko; Xiaodong Wang; Carrow Wells; Timothy M Willson; Stephen V Frye; Jessica E Young; Alison D Axtman
Journal:  Alzheimers Dement (N Y)       Date:  2022-04-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.